Revolutionizing Cancer Trial Matching: PCC and Massive Bio’s AI-driven Multi-sponsor Study Delivers Promising Results

June 2024, ASCO Annual Meeting, Chicago – The Precision Cancer Consortium (PCC), in partnership with Massive Bio, has unveiled compelling results from a comprehensive study conducted on a multi-sponsor pharmaceutical platform. This study rigorously tested Massive Bio’s existing artificial intelligence (AI) system, designed to refine the clinical trial matching process using real-world clinical and genomic […]

Unique clinical trial matching initiative increases patient eligibility for trials

The problem: Clinical research teams manually match patients one-trial-at-a-time, taking approximately 25 minutes per trial. This limits patients’ choices and clinical trial enrolment rates. The solution: In 2023 a collaborative project between PCC and Massive Bio was initiated to find more eligible patients for biomarker-directed clinical trials by pre-screening all patients with NGS test results […]